Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
MEDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$250.05 - $501.30
Previous CloseN/A
Volume64.09K
Average Volume (3M)623.20K
Market Cap
$13.18B
Enterprise Value$9.25B
Total Cash (Recent Filing)$46.33M
Total Debt (Recent Filing)$124.95M
Price to Earnings (P/E)34.9
Beta1.17
Next Earnings
Oct 27, 2025EPS Estimate
3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.10
Shares Outstanding28,093,025
10 Day Avg. Volume337,197
30 Day Avg. Volume623,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue4.14
Enterprise Value/Gross Profit13.11
Enterprise Value/Ebitda18.85
Forecast
1Y Price Target
$411.50Price Target Upside-13.09% Downside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Business OutlookNet new business awards came in above the model, leading to a higher-than-expected book-to-bill ratio for the period.
Quarterly PerformanceMEDP's strong quarterly performance exceeded low expectations, which contributed to a significant stock price increase.
Revenue GrowthLower levels of cancellations and higher request for proposal activities are promising factors for future revenue growth.
Bears Say
Price MultiplesThe move has overshot the mark, as current share prices are back to peak multiples from last year without the same expected EPS acceleration.
Stock DowngradeThe analyst downgraded shares of MEDP to Sell from Hold, as the recent 55% move is believed to reflect short covering rather than a material change in fundamentals.
Stock ValuationShares are considered overvalued at 31 times the revised estimates relative to expected growth.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $250.05 and its highest was $501.30 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $13.18B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Oct 27, 2025 which is in 59 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Jul 21, 2025. The company reported $3.1 earnings per share for the quarter, beating the consensus estimate of $2.983 by $0.117.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Overvalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 3.53.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 28,093,025 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $3.1 in its last earnings report, beating expectations of $2.983. Following the earnings report the stock price went up 54.665%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$411.50 (-13.09% Downside)
$411.50 (-13.09% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 44.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.79%
12-Months-Change
Fundamentals
Return on Equity
89.38%
Trailing 12-Months
Asset Growth
-18.14%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. is a global clinical contract research organization (CRO) that provides comprehensive services for the pharmaceutical, biotechnology, and medical device industries. The company specializes in managing the development of new drugs and therapies, offering expertise in clinical trial management, regulatory affairs, and data management. Medpace operates in various therapeutic areas, including oncology, cardiology, and central nervous system disorders, aiming to support its clients from the initial stages of drug development through to regulatory approval and commercialization.
MEDP Company Deck
MEDP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and improved financial guidance, driven by a strong funding environment and lower cancellations, despite a decrease in backlog and modest net income growth. The sentiment is positive overall due to the outweighing positive financial metrics and outlook.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$411.50
▼(-13.09% Downside)
Technical Analysis
Ownership Overview
20.82% Insiders
24.04% Mutual Funds
33.27% Other Institutional Investors
0.32% Public Companies and
Individual Investors